{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:02:02Z","timestamp":1781478122005,"version":"3.54.1"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"abstract":"<jats:p>Objective. Standard treatment of central precocious puberty (CPP) consists of intramuscular or subcutaneous administration of a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) at 3- to 4-week intervals. Although generally effective in suppressing clinical and laboratory parameters of puberty, GnRHa injections are painful, and the need for monthly clinic visits may contribute to poor compliance. Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 \u03bcg\/day. The aims of this study were to determine if a histrelin implant would suppress gonadotropin and estradiol (E2) in girls with CPP for 1 year and to compare the suppression to standard treatment.<\/jats:p>\n               <jats:p>Methods. We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression. Mean age at diagnosis was 6 years (range: 2\u20139 years). GnRH (100 \u03bcg intravenously) stimulation tests (GnRH-STs) showed peak luteinizing hormone and follicle-stimulating hormone responses of 23 \u00b1 28 (mean \u00b1 SD) and 20 \u00b1 25 mIU\/mL, respectively. All subjects were initially treated with depot intramuscular GnRHa triptorelin embonate. Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued. Six girls were followed for 15 months after insertion (group A). For the remaining 5 girls, the implant was removed after 9 months, and a new implant was inserted at the same incision site (group B). GnRH-STs were performed before depot GnRHa treatment, immediately before implant insertion, at the 6- and 9-month visits for each patient and the 12- and 15-month visit for those girls followed for 15 months.<\/jats:p>\n               <jats:p>Results. In all girls, breast development regressed, growth velocity decreased, and bone-age advancement was slowed. Basal gonadotropins and their responses to GnRH-STs and E2 levels were suppressed. Peak luteinizing hormone and follicle-stimulating hormone responses to GnRH-STs at preinsertion versus 9 months were 1.30 \u00b1 1.34 vs 0.25 \u00b1 0.08 and 1.68 \u00b1 1.08 vs 1.13 \u00b1 0.55 mIU\/mL, respectively. Basal and stimulated gonadotropin levels and E2 level remained suppressed in all 6 patients followed for 15 months after implant insertion. Patients and parents reported less pain and discomfort and less interference with school activity and work with the implant compared with standard monthly injections.<\/jats:p>\n               <jats:p>Conclusions. The histrelin implant consistently suppresses clinical and laboratory parameters of puberty for 1 year and is a promising new technique for treating CPP without the pain and inconvenience of monthly injections.<\/jats:p>","DOI":"10.1542\/peds.2005-0538","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T20:44:17Z","timestamp":1133469857000},"page":"e798-e802","source":"Crossref","is-referenced-by-count":52,"title":["The Histrelin Implant: A Novel Treatment for Central Precocious Puberty"],"prefix":"10.1542","volume":"116","author":[{"given":"Harry J.","family":"Hirsch","sequence":"first","affiliation":[{"name":"Pediatric Day Hospital"},{"name":"Institute of Hormone Research, Shaare Zedek Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gillis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Pediatric Endocrinology Clinic, Hadassah University Hospital, Ein-Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Strich","sequence":"additional","affiliation":[{"name":"Specialty Pediatric Clinics, Endocrinology and Diabetes, Clalit Health Service, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Chertin","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amicur","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzina","family":"Lindenberg","sequence":"additional","affiliation":[{"name":"Institute of Hormone Research, Shaare Zedek Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadassa","family":"Gelber","sequence":"additional","affiliation":[{"name":"Institute of Hormone Research, Shaare Zedek Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving M.","family":"Spitz","sequence":"additional","affiliation":[{"name":"Institute of Hormone Research, Shaare Zedek Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,12,1]]},"reference":[{"key":"2021121003213812000_R1","doi-asserted-by":"crossref","unstructured":"Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics.\u20081997;99:505\u2013512","DOI":"10.1542\/peds.99.4.505"},{"key":"2021121003213812000_R2","doi-asserted-by":"crossref","unstructured":"Traggiai C, Stanhope R. Disorders of pubertal development. Best Pract Res Clin Obstet Gynaecol.\u20082003;17:41\u201356","DOI":"10.1053\/ybeog.2003.0360"},{"key":"2021121003213812000_R3","doi-asserted-by":"crossref","unstructured":"Klein KO. Precocious puberty: who has it? Who should be treated?J Clin Endocrinol Metab.\u20081999;84:411\u2013414","DOI":"10.1210\/jcem.84.2.5533"},{"key":"2021121003213812000_R4","doi-asserted-by":"crossref","unstructured":"Grumbach MM. The neuroendocrinology of human puberty revisited. Horm Res.\u20082002;57(suppl 2):2\u201314","DOI":"10.1159\/000058094"},{"key":"2021121003213812000_R5","doi-asserted-by":"crossref","unstructured":"Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab.\u20082002;16:165\u2013189","DOI":"10.1053\/beem.2002.0188"},{"key":"2021121003213812000_R6","doi-asserted-by":"crossref","unstructured":"Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol.\u20082000;163:838\u2013844","DOI":"10.1016\/S0022-5347(05)67816-0"},{"key":"2021121003213812000_R7","doi-asserted-by":"crossref","unstructured":"Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB Jr. Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab.\u20081988;67:474\u2013479","DOI":"10.1210\/jcem-67-3-474"},{"key":"2021121003213812000_R8","doi-asserted-by":"crossref","unstructured":"Neely EK, Hintz RL, Wilson DM, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr.\u20081995;127:40\u201346","DOI":"10.1016\/S0022-3476(95)70254-7"},{"key":"2021121003213812000_R9","doi-asserted-by":"crossref","unstructured":"Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics.\u20082002;109(2): Available at:www.pediatrics.org\/cgi\/content\/full\/109\/2\/e30","DOI":"10.1542\/peds.109.2.e30"},{"key":"2021121003213812000_R10","unstructured":"Kuzma P, Moo-Young A, Spitz I, et al. Hydron implant for continuous treatment of prostate cancer: twelve months and beyond. Presented at: Annual Meeting of Biomaterials; April 28\u2013May 2, 1999; Providence, RI"},{"key":"2021121003213812000_R11","doi-asserted-by":"crossref","unstructured":"Brito VN, Batista MC, Borges MF, et al. Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab.\u20081999;84:3539\u20133544","DOI":"10.1210\/jc.84.10.3539"},{"key":"2021121003213812000_R12","unstructured":"Tanner JM, Whitehouse RH, Cameron N, Marshall WA, Healy MJR, Goldstein H. Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method). London, United Kingdom: Academic Press; 1983"},{"key":"2021121003213812000_R13","doi-asserted-by":"crossref","unstructured":"Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press; 1959","DOI":"10.1097\/00000441-195909000-00030"},{"key":"2021121003213812000_R14","unstructured":"Kuczmarski RJ, Ogden CL, Grummer Strawn LM, et al. CDC growth charts: United States. Adv Data.\u20082000;(314):1\u201327"},{"key":"2021121003213812000_R15","unstructured":"Roger M, Lahlou N, Chaussain JL. Gonadotropin-releasing hormone testing in pediatrics. In: Ranke MB, ed. Diagnostics of Endocrine Function in Children and Adolescents. Heidelberg, Germany: Johann Ambrosius Barth Verlag; 1996:346\u2013369"},{"key":"2021121003213812000_R16","doi-asserted-by":"crossref","unstructured":"Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab.\u20082000;13(suppl 1):723\u2013737","DOI":"10.1515\/JPEM.2000.13.S1.723"},{"key":"2021121003213812000_R17","doi-asserted-by":"crossref","unstructured":"Carel JC, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab.\u20082002;87:4111\u20134116","DOI":"10.1210\/jc.2001-020243"},{"key":"2021121003213812000_R18","doi-asserted-by":"crossref","unstructured":"Salerno M, Di Maio S, Tenore A. Monitoring therapy for central precocious puberty [letter]. Pediatrics.\u20082002;110:1255","DOI":"10.1542\/peds.110.6.1255"},{"key":"2021121003213812000_R19","doi-asserted-by":"crossref","unstructured":"Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol (Oxf).\u20082002;56:129\u2013148","DOI":"10.1046\/j.0300-0664.2001.01490.x"},{"key":"2021121003213812000_R20","doi-asserted-by":"crossref","unstructured":"Alonso LC, Rosenfield RL. Oestrogens and puberty. Best Pract Res Clin Endocrinol Metab.\u20082002;16:13\u201330","DOI":"10.1053\/beem.2002.0177"},{"key":"2021121003213812000_R21","doi-asserted-by":"crossref","unstructured":"Oostdijk W, Hummelink R, Odink RJ, et al. Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist. Eur J Pediatr.\u20081990;149:308\u2013313","DOI":"10.1007\/BF02171554"},{"key":"2021121003213812000_R22","doi-asserted-by":"crossref","unstructured":"Pescovitz OH, Barnes KM, Cutler GB Jr. Effect of deslorelin dose in the treatment of central precocious puberty. J Clin Endocrinol Metab.\u20081991;72:60\u201364","DOI":"10.1210\/jcem-72-1-60"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/6\/e798\/1067514\/zpe0120500e798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/6\/e798\/1067514\/zpe0120500e798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T09:58:32Z","timestamp":1639130312000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/116\/6\/e798\/62977\/The-Histrelin-Implant-A-Novel-Treatment-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,12,1]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-0538","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}